Gilead Sciences Inc. (GILD) announced interim results from a single-arm, open-label Phase 2 study evaluating idelalisib, an investigational, targeted, oral inhibitor of PI3K delta, for the treatment of patients with indolent non-Hodgkin's lymphoma that is non-responsive to rituximab and to alkylating-agent-containing chemotherapy.
In the study, single-agent treatment with idelalisib achieved an overall response rate of 53.6 percent, with a median duration of response at this interim analysis of 11.9 months.
The most common adverse event was diarrhea. Sixteen percent of patients discontinued due to adverse events.
For comments and feedback: editorial@rttnews.com